Diagnostic performance of quantitative ultrasound parameters in assessing hepatic steatosis in NAFLD with MRI PDFF as the reference standard a prospective non randomized cohort study - NI

Samsung Medison Co.Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1. Patients who clinically suspected MASLD based on EASL–EASD–EASO Clinical Practice
•Guidelines for the management of Metabolic Dysfunction-Associated Steatotic Liver Disease
•(MASLD), or patients who recommended to undergo either abdominal ultrasound
•examination or liver MRI examination
•2. Male or Female of Age =18 years ,
•3. Individuals who have decided to participate in the clinical study on their own will and have
•provided the informed consent after reading/hearing and fully understanding the detailed explanations regarding the clinical study.

•1. Subject who has disagreed the signing of informed consent form for this study
•2. Subject who has a history of chronic liver disease due to etiology other than MASLD.
•3. Subject who had a daily alcohol consumption ?30 g for men and ?20 g for women based on
•EASL– ASD–EASO Clinical Practice Guidelines for the management of metabolic dysfunction associated steatotic liver disease (MASLD)
•4. Subject who has a history of long-term use of hepatotoxic drugs.
•5. Subject with acute liver failure
•6. Subject who has a history of esophageal varix, hydrops abdominis, hepatic coma, as well as
•patents with signs of acute biliary obstruction, or those who had recent liver surgery.
•7. Woman who is pregnant

发起方

Samsung Medison Co.Ltd